Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
138
-
Total shares
-
118M
-
Shares change
-
+19.7M
-
Total reported value, excl. options
-
$122M
-
Value change
-
+$20M
-
Put/Call ratio
-
0.52
-
Number of buys
-
50
-
Number of sells
-
-57
-
Price
-
$1.03
Significant Holders of HERON THERAPEUTICS, INC. /DE/ - COM (HRTX) as of Q3 2023
138 filings reported holding HRTX - HERON THERAPEUTICS, INC. /DE/ - COM as of Q3 2023.
HERON THERAPEUTICS, INC. /DE/ - COM (HRTX) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 118M shares
.
Largest 10 shareholders include Rubric Capital Management LP (26.7M shares), VANGUARD GROUP INC (8.17M shares), BAKER BROS. ADVISORS LP (8.13M shares), BlackRock Inc. (8.13M shares), Velan Capital Investment Management LP (6.99M shares), FRANKLIN RESOURCES INC (6.96M shares), JPMORGAN CHASE & CO (6.81M shares), Clearline Capital LP (6.15M shares), GREAT POINT PARTNERS LLC (4.74M shares), and PALISADE CAPITAL MANAGEMENT, LP (4.11M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.